Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

April Stowers

Nurse Practitioner, Family Lee, FL Nurse Practitioner

NPI 1003202805 CMS profile 10413247

28420 Bonita Crossings Blvd Unit 100, Lee, FL 34135

Open in the dashboard

General payments

$89,317

664 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, April Stowers of Lee, FL is reported in the CMS Open Payments database as having received $89,317 across 664 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,337 161
2024 General $30,452 192
2023 General $8,231 149
2022 General $6,769 114
2021 General $1,527 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • April Stowers
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to April Stowers were reported at $42,337. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year April Stowers Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,527 $124 $35–$379 $132
2022 $6,769 $141 $44–$430 $149
2023 $8,231 $154 $49–$476 $160
2024 $30,452 $165 $51–$504 $164
2025 $42,337 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $41,706 170 payments
  2. Eisai Inc. $33,918 146 payments
  3. Eli Lilly and Company $4,735 10 payments
  4. Biogen, Inc. $1,151 27 payments
  5. AbbVie, Inc. $995 36 payments
  6. UCB, Inc. $853 32 payments
  7. Ge Healthcare $719 26 payments
  8. Alnylam Pharmaceuticals Inc. $456 21 payments
  9. Corium, Inc. $347 13 payments
  10. Amgen Inc. $325 12 payments
  11. Other $4,112 171 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,189 34 payments
  2. Travel and Lodging $23,145 81 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $16,958 44 payments
  4. Food and Beverage $15,298 491 payments
  5. Consulting Fee $9,728 14 payments
Products named General payments · program years 2021–2025
  1. Leqembi $33,682 138 payments
  2. KISUNLA $24,820 88 payments
  3. ADUHELM $689 10 payments
  4. UBRELVY $627 19 payments
  5. Briviact $587 20 payments
  6. ONPATTRO $456 21 payments
  7. AMYVID Neuroscience $376 15 payments
  8. AMYVID Neuroscience $365 21 payments
  9. ADLARITY $347 13 payments
  10. NURTEC ODT $340 13 payments
  11. Other $5,748 244 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

471

Median for Nurse Practitioner: 389

Drug cost

$68,919

Median for Nurse Practitioner: $21,885

Branded share of claims

11.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 22 $47,120
Rivastigmine Generic 55 $13,386
Memantine Hcl Generic 111 $3,967
Donepezil Hcl Generic 209 $3,689
Rosuvastatin Calcium Generic 14 $283
Citalopram Hbr Citalopram Hydrobromide Brand 31 $258
Sertraline Hcl Generic 14 $136
Escitalopram Oxalate Generic 15 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$147,897

Medicare's payments for the services billed

Medicare patients

354

Average age 79

Services billed

7,204

193 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Alzheimer's or dementia 67%
Arthritis 53%
Ischemic heart disease 36%
Depression 34%
Chronic kidney disease 23%
Diabetes 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISUNLA
$8,639 — —
Leqembi
$6,589 — —
AMYVID
$198 — —
INGREZZA
$197 — —
ONPATTRO
$174 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

664 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record